The present specification provides methods of treatment of flavivirus infection, such as Zika or dengue vims infection, by administration of gossypol, a gossypol derivative, digitonin, or conessine. These compounds may be used alone, in combination with each other, or in combination with curcumin or bortezomib.

The present specification provides methods of treatment of flavivirus infection, such as Zika or dengue vims infection, by administration of gossypol, a gossypol derivative, digitonin, or conessine. These compounds may be used alone, in combination with each other, or in combination with curcumin or bortezomib.

The present specification provides methods of treatment of flavivirus infection, such as Zika or dengue vims infection, by administration of gossypol, a gossypol derivative, digitonin, or conessine. These compounds may be used alone, in combination with each other, or in combination with curcumin or bortezomib.

Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.

Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.

Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

Disclosed herein are antimicrobial compounds, polymorphic forms, compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs). The boronic acid derivatives disclosed herein can be used in combination with various antibiotics to treat resistant bacteria.

A lubric gel composition for personal defense includes a fatty acid at a concentration ranging from 5 wt % to 10 wt % of the composition, a thickening agent at a concentration ranging from 1.75 wt % to 8.75 wt % of the composition, a detergent at a concentration ranging from 1.03 wt % to 4.07 wt % of the composition, a surfactant at a concentration ranging from 2 wt % to 15 wt % of the composition, and water at a concentration ranging from 66 wt % to 90.21 wt % of the composition.